Novartis, BMS pause cell therapy trials; $480K cancer drug price becomes routine

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, signaling potential safety or efficacy concerns in a key oncology modality. Separately, a $480,000 price tag for a cancer drug is now described as routine, highlighting escalating treatment costs. The trial pauses could affect pipeline timelines and investor sentiment for these companies, while the pricing trend underscores broader affordability pressures in oncology.